Canopy Growth Corporation
HealthcareNASDAQ:CGC · NASDAQ Global Select
-$0.01 today
Vol 6.35M · Avg 9.95M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$306.1M of revenue converted into -$349.9M of net income for the selected period. Gross margin is 25.7% and net margin is -120.9%, showing how much revenue survives after costs and taxes. EPS is $-1.91, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $269.0M -9.5% | $297.1M -10.8% | $333.3M -29.9% | $475.7M -13.0% | $546.6M | $921.6M | $731.2M | $843.2M |
| Cost of Revenue | $189.5M -12.4% | $216.3M -45.5% | $396.8M -40.2% | $663.1M +38.2% | $479.7M | $804.0M | $882.4M | $1.3B |
| Gross Profit | $79.5M -1.7% | $80.9M +227.3% | -$63.5M +66.1% | -$187.4M -379.9% | $67.0M | $7.6B | $6.2B | $4.9B |
| Gross Margin | 29.6% +2.3pp | 27.2% +46.3pp | -19.1% +20.3pp | -39.4% -51.6pp | 12.2% | 28.9% | 38.3% | 12.3% |
| Research & Development | $0 -100.0% | $4.6M -78.8% | $21.7M -32.7% | $32.3M -44.0% | $57.6M | $1.3B | $490.4M | $1.1B |
| Selling, General & Admin | $121.7M -32.6% | $180.6M -39.4% | $298.0M -17.5% | $361.1M -31.1% | $523.8M | $923.0M | -$1.5B | $732.6M |
| Operating Expenses | $196.7M -36.5% | $309.6M -87.9% | $2.6B +208.8% | $831.4M -36.6% | $1.3B | $7.0B | $8.7B | $7.3B |
| Depreciation & Amortization | $43.1M -18.9% | $53.2M -33.6% | $80.0M -27.9% | $110.9M -12.7% | $127.1M | $1.2B | $631.8M | $1.5B |
| EBITDA | -$479.3M -53.2% | -$312.8M +89.1% | -$2.9B -5336.5% | -$53.0M +88.2% | -$449.7M | $6.8B | $9.3B | $11.9B |
| EBITDA Margin | -178.2% -72.9pp | -105.3% +758.9pp | -864.2% -853.1pp | -11.1% +71.1pp | -82.3% | 46.3% | 42.0% | 37.7% |
| Operating Income | -$117.1M +48.8% | -$228.7M +91.3% | -$2.6B -158.2% | -$1.0B +18.1% | -$1.2B | $14.0B | -$15.7B | $14.3B |
| Operating Margin | -43.5% +33.4pp | -77.0% +712.4pp | -789.3% -575.2pp | -214.2% +13.3pp | -227.5% | 24.1% | 22.0% | 29.5% |
| Interest Income | $8.8M -45.7% | $16.2M -33.1% | $24.3M +267.9% | $6.6M -69.1% | $21.4M | -$1.6B | $405.0M | $561.8M |
| Interest Expense | $74.6M -29.2% | $105.4M -16.5% | $126.2M +21.4% | $103.9M +1128.8% | $8.5M | $1.0B | $1.2B | $1.3B |
| Other Income / Expenses | -$479.9M -97.8% | -$242.6M +46.7% | -$455.6M -160.7% | $750.9M +270.5% | -$440.5M | $1.4B | $1.2B | $1.1B |
| Income Before Tax | -$597.0M -26.7% | -$471.4M +84.7% | -$3.1B -1052.2% | -$267.9M +84.1% | -$1.7B | $4.9B | $3.6B | $5.3B |
| Pre-Tax Margin | -221.9% -63.3pp | -158.6% +767.4pp | -926.1% -869.8pp | -56.3% +251.7pp | -308.1% | 18.7% | 26.2% | 24.1% |
| Income Tax Expense | $7.1M -42.1% | $12.3M +315.2% | -$5.7M +36.0% | -$8.9M +31.9% | -$13.1M | -$1.6B | $745.2M | $1.0B |
| Net Income | -$598.1M +9.0% | -$657.3M +80.0% | -$3.3B -957.3% | -$310.0M +82.2% | -$1.7B | $4.8B | $4.7B | -$15.5B |
| Net Margin | -222.4% -1.2pp | -221.2% +762.5pp | -983.7% -918.5pp | -65.2% +254.0pp | -319.2% | 17.5% | 22.5% | 27.5% |
| EPS (Basic) | -$6 +14.5% | -$6 +90.8% | -$71 -818.2% | -$8 -73.0% | -$4 | $703.2M | $1.3B | $512.8M |
| EPS (Diluted) | -$6 +37.1% | -$9 +87.6% | -$71 -818.2% | -$8 -73.0% | -$4 | $609.4M | $452.6M | $598.2M |
| Weighted Avg Shares | $107.6M +5.8% | $101.6M +119.2% | $46.4M +18.5% | $39.1M -89.6% | $375.3M | $925.8M | $1.1B | $1.3B |
| Weighted Avg Shares (Diluted) | $107.6M +43.8% | $74.8M +61.3% | $46.4M +18.5% | $39.1M -89.6% | $375.7M | $924.4M | $678.0M | -$1.5B |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
BioAge Labs, Inc.
NASDAQ:BIOA
$679.20M
Ironwood Pharmaceuticals, Inc.
NASDAQ:IRWD
$600.84M
Aclaris Therapeutics, Inc.
NASDAQ:ACRS
$520.97M
Cabaletta Bio, Inc.
NASDAQ:CABA
$490.79M
Lyell Immunopharma, Inc.
NASDAQ:LYEL
$315.01M
Alpha Teknova, Inc.
NASDAQ:TKNO
$225.18M
Lifecore Biomedical, Inc.
NASDAQ:LFCR
$211.55M
Owens & Minor, Inc.
OMI
$207.07M
Aurora Cannabis Inc.
NASDAQ:ACB
$172.40M
Definitive Healthcare Corp.
NASDAQ:DH
$88.59M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does CGC generate?
Canopy Growth Corporation (CGC) reported $269.00M of revenue in fiscal 2024.
Is CGC profitable?
Canopy Growth Corporation (CGC) reported -$598,115,000.00 of net income, with a net margin of -222.4%.
Explore More
Continue the stock analysis
Jump to another research area for this company.